- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04775043
Study Evaluating Hot Flashes in Hormone Sensitive Breast Cancer (HOTSHOT)
Etude Observationnelle de Cohorte Prospective évaluant Les bouffées de Chaleur Sur Deux Populations de Patientes : Population témoin et Patientes Sous hormonothérapie Adjuvante Pour un Cancer du Sein Hormonosensible
The validation of the HFRDIS questionnaire in French will allow the use in common practice of this questionnaire in consultation in order to have a concrete and reproducible assessment of the impact of hot flashes on the daily life of patients. This validation will also allow this questionnaire to be used in therapeutic trials to assess the effectiveness of a symptomatic treatment under study.
The use of this questionnaire in patients on hormone therapy will allow for an overall assessment of the impact of hot flashes in their daily lives.
There are no risks induced by participation in this research, it is only an observational study without change on the monitoring of participants in both cohorts.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective is to assess the impact of hot flashes on the daily lives of patients on adjuvant hormone therapy for hormone-sensitive breast cancer.
The primary test of judgment is composite. The first step is a French validation of the HFRDIS questionnaire assessing the impact of hot flashes on daily life in a control population free of breast cancer (validated in English). The second step is a comparison of the impact of hot flashes on the quality of life of patients in both populations (control and hormone therapy adjuvant for hormone-sensitive breast cancer) via the HFRDIS questionnaire.
In the first part of the study (control population): Patients will be seen in a city gynecology consultation. Patients between the ages of 40 and 60 will be offered participation in the study consecutively. If patients answer "yes" to the question "Do you have hot flashes?", they will then be included in the study and will have access to the study questionnaire. Upon their 2nd connection on the website (D15), patients will answer the HFRDIS Questionnaire again.
In the second part of the study (patients on hormone therapy for breast cancer): Patients at the Institut Curie Saint Cloud aged 40 to 60 years included on hormone therapy adjuvant therapy who will be seen in a monitoring consultation will be offered participation in the study consecutively.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Saint-Cloud, France, 92110
- Institut Curie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Group for control population: Patient aged 40 to 60 included.
- Group for Hormone therapy for breast cancer: Patient aged 40 to 60 included management for RH breast cancer under hormone therapy adjuvant therapy:
Description
Inclusion criteria:
Control population:
- Patient aged 40 to 60 included.
- Patient with internet access and email address.
- Patient affiliated with a social security system, speaking and reading French.
- Collection of non-opposition to participation in the study.
Hormone therapy for breast cancer
- Patient aged 40 to 60 included management for RH breast cancer under hormone therapy adjuvant therapy:
- Patient with internet access and email address.
- Patient affiliated with a social security system, speaking and reading French.
- Collection of consent to participate in the study.
Exclusion criteria:
Control population:
- Patient with a personal history of breast cancer.
- Patient with another cancer in the course of treatment.
- Woman with a life expectancy < 6 months at the time of diagnosis (in relation to other serious chronic conditions).
- Persons deprived of their liberty or under guardianship.
- Inability to submit to the medical follow-up of the study for social or psychological reasons.
Hormone therapy patients for breast cancer:
- Patient currently recurrent with breast cancer.
- Patient in metastatic breast cancer.
- Woman with a life expectancy < 6 months at the time of diagnosis (in relation to other serious chronic conditions).
- Persons deprived of their liberty or under guardianship.
- Inability to submit to the medical follow-up of the trial for social or psychological reasons.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Control population
First part of the study for the HFRDIS Questionnaire French validation
|
HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
|
Patients on hormone therapy for breast cancer
Second par of the study for the HFRDIS questionnaire use on patients on hormone therapy for breast cancer
|
HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score at the Hot Flash Related Daily Interference Scale
Time Frame: Day 1
|
The score is calculated with 10 questions ticked from 0 to 10.
The highest numbers are a higher degree of impact on the participant Life.
If the participant are not prone to hot flashes or if hot flashes do not no impact on these aspects of her life, she checks "0" for all categories.
The total score of a scale ranges from 0 to 100.
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Delphine HEQUET, Dr, Institut Curie Saint-Cloud
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IC 2020-15
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on HFRDIS questionnaire completion
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...Not yet recruiting
-
Institut Claudius RegaudLigue contre le cancer, FranceRecruiting
-
Assistance Publique Hopitaux De MarseilleRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedHereditary Spastic ParaplegiaFrance
-
Democritus University of ThraceCompleted
-
University Hospital, Clermont-FerrandMerck Santé SASUnknownCognitive Dysfunction | Sclerosis, MultipleFrance
-
University Hospital, AngersUnknownIdiopathic Thrombocytopenic PurpuraFrance
-
University Hospital, AngersCompletedFood Allergy in Children | 6 Years Old MaximumFrance
-
Hospices Civils de LyonCompleted